Current filters:


Popular Filters

8047 to 8071 of 8854 results

Celgene to drop Revlimid in CR prostate cancer following Ph III trial failure


There was disappointment for blockbuster for multiple myeloma drug Revlimid (lenalidomide) when the Swiss…


Problems identified in Canada’s drug regulatory system


A report presented to the Canadian Parliament this week by John Wiersema, Interim Auditor General of…

North AmericaPharmaceuticalRegulation

EMA makes interim recommendations to deal with shortcomings at Ben Venue Labs


The European Medicines Agency (EMA) is currently reviewing shortcomings in quality assurance identified…

Boehringer IngelheimEuropeMarkets & MarketingNorth AmericaPharmaceuticalRegulation

Indian HIV drugs market forecast to reach $54 million by 2014


The market for HIV drugs in India is expected to reach 454 million by 2014, according to a new report…

Anti-viralsAsia-PacificGenericsMarkets & MarketingPharmaceutical

Merck & Co to pay $950 million for illegal marketing of Vioxx


US pharma giant Merck & Co (NYSE: MRK) has agreed to pay $950 million to resolve criminal charges and…

FinancialLegalMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalVioxx

Pfizer to buy Excaliard, gaining rights to Ph II skin scarring product


Global pharma behemoth Pfizer (NYSE: PFE) says it has entered into a definitive agreement to acquire…

DermatologicalsExcaliard PharmaIsis PharmaceuticalsMergers & AcquisitionsPfizerPharmaceutical

UCB adds to CNS portfolio with acquisition of Lectus’ key pharmaceutical assets


Belgian drugmaker UCB (Euronext Brussels: UCB) has acquired the key pharmaceutical assets of closely-held,…

Lectus TherapeuticsMergers & AcquisitionsNeurologicalPharmaceuticalResearchUCB

FDA accepts NDA for Lundbeck and Otsuka’s aripiprazole depot formulation


Danish CNS drug specialist Lundbeck (LUND: DC) and its new partner Japan’s Otsuka Pharmaceutical…

aripiprazole depotLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Novartis gains NIH listing in Japan for Ilaris


Swiss drug major Novartis’ (NOVN: VX) Ilaris (canakinumab), a treatment for cryopyrin-associated…

Anti-Arthritics/RheumaticsAsia-PacificIlarisNovartisPharmaceuticalPricingRare diseases

Andromeda’s type 1 diabetes candidate DiaPep277 meets Ph III primary endpoint


Israel-based Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (TASE: CBI.TA), says initial…

AndromedaBiotechnologyClal BiotechnologyDiabetesDiaPep277ResearchTeva Pharmaceutical Industries

Promotions at Par Pharma as firm grows with acquisitions


US generics drugmaker Par Pharmaceutical (NYSE: PRX) has promoted Thomas Haughey to the role of president…

GenericsManagementPar Pharmaceutical

New Australian paper shows need to complete clinical trial plan


A Medicines Australia paper launched at Parliament House yesterday (November 22) shows the federal government’s…


Gilead expands hepatitis C R&D portfolio with $11 billion buy of Pharmasset


In its biggest M&D deal to date, Gilead Sciences (Nasdaq: GILD) says it has signed a definitive agreement…

Anti-viralsBiotechnologyGilead SciencesMergers & AcquisitionsmericitabinePharmaceuticalPharmasset

Valeant to acquire Australia’s iNova for up to $946 million


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (NYSE: VRX and TSX: VRX) has signed…

BiotechnologyiNovaMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

FDA backs EUSA Pharma’s orphan leukemia drug Erwinaze


UK and USA-based specialty drug firm EUSA Pharma says that the US Food and Drug Administration has approved…

ErwinazeEUSA PharmaNorth AmericaPharmaceuticalRare diseasesRegulation

Adeona Pharma and Intrexon collaborate for synthetic DNA-based PAH therapy


USA-based Adeona Pharmaceuticals (NYSE Amex: AEN) and the Human Therapeutics Division of Intrexon Corp…

Adeona PharmaCardio-vascularIntrexonLicensingPharmaceuticalResearchRespiratory and Pulmonary

USA’s CMS to cover infusion costs associated with Dendreon’s Provenge


Sales of Dendreon’s (Nasdaq: DNDN) new prostate cancer treatment Provenge (sipuleucel-T) have been…

BiotechnologyDendreonNorth AmericaOncologyPharmaceuticalPricingProvengeRegulation

Turkish Pharma and Health Ministry defend clinical trials record


The Turkish Ministry of Health and the country’s Association of Research-Based Pharmaceutical Companies…


Hepatitis C drug market in Mexico expected to double to $104 million in 2015


The hepatitis C virus (HCV) market in Mexico will nearly double from $56 million in 2010 to $104 million…

Anti-viralsIncivekMarkets & MarketingMerck & CoPharmaceuticalRocheSouth AmericaVertexVictrelis

Taiwan pharmaceutical exports rise 6.2% in 3rd-qtr 2011


Year-on-year exports by Taiwan's pharmaceutical industry for the third quarter of this year saw a rise…

Asia-PacificGenericsMarkets & MarketingPharmaceutical

8047 to 8071 of 8854 results

Back to top